Pipeline
Precision oncology therapeutics designed to control oncogenic proliferation, tumor survival, and adaptive resistance.
Alaw Therapeutics is developing a next-generation precision oncology pipeline integrating highly selective kinase inhibitors and RIPTAC therapeutics to address some of the most challenging mechanisms of tumor progression, therapeutic escape, and intracranial disease.
Our platform is focused on high-value oncogenic pathways that drive cell-cycle progression, transcriptional dependency, and tumor survival across aggressive solid tumors, including cancers with CNS involvement and brain metastases.
Current therapies often fail due to adaptive rewiring of tumor biology, including compensatory signaling, transcriptional escape, and acquired resistance mechanisms. Alaw’s integrated approach is designed to suppress these escape pathways through selective targeting of multiple complementary tumor-control mechanisms.
Our pipeline includes:
Selective brain-penetrant CDK4 inhibitor (AL-433) designed to control early cell-cycle progression while minimizing CDK6-associated hematologic toxicity.
Selective brain-penetrant CDK2 inhibitor (AL-605) engineered to suppress compensatory proliferative escape mechanisms associated with Cyclin E and CDK2 activation.
Next-generation RIPTAC therapeutics designed for tumor-selective pathway control through targeted degradation and localized modulation of oncogenic signaling networks.
By combining differentiated selectivity, CNS penetration, and precision pathway control, Alaw aims to develop transformative therapies for resistant and aggressive cancers with limited treatment options.